Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer
Lung Neoplasms
About this trial
This is an interventional diagnostic trial for Lung Neoplasms focused on measuring Positron Emission Tomography, Fluorodeoxyglucose F18, Tomography scanners, X-Ray Computed
Eligibility Criteria
Inclusion Criteria: Male or female Histologically proven, resected lung cancer of the following histologic types: squamous cell carcinoma; adenocarcinoma; undifferentiated large cell carcinoma; non-small cell; and not otherwise specified. Age equal to or greater than 18 years American Joint Committee (AJC) Stage I-III disease (if all detectable tumours can be encompassed by radiation therapy fields, including both the primary tumour and the involved lymph nodes); patients with positive supraclavicular nodes (N3) are not eligible Able and willing to follow instructions and comply with the protocol Provide written informed consent prior to participation in this study Karnofsky Performance Scale score equal to or greater than 70 Measurable disease on the CT and PET images Patient must be deemed eligible for the radical combined-modality therapy. Exclusion Criteria: Nursing or pregnant females MI disease N3 disease (patients with positive supraclavicular nodes are not eligible) Karnofsky performance status less than 70 Patients who have undergone complete tumour resection Patients with post-resection intrathoracic tumour recurrence Evidence of small cell history Age less than 18 years Prior or concurrent malignancy except non-melanomatous skin cancer (unless disease free for at least 5 years) Prior radiotherapy to the thorax or neck Prior chemotherapy Patients with myocardial infarction within the preceding 6 months or symptomatic heart disease, including angina; congestive heart failure; and uncontrolled arrythmias Inability to maintain a state of deep inspiratory breath-hold for a minimum length of time
Sites / Locations
- Cross Cancer Institute